MDNA213 / Medicenna - LARVOL DELTA

Characterization of MDNA113, a tumor-targeting anti-PD1-IL-2SK immunocytokine with conditional activation to increase tolerability and maximize efficacy (AACR 2024) - "Background-MDNA113 consists of an IL-13 decoy receptor-binding domain (MDNA213) fused to anti-PD1-IL-2SK (MDNA223) immunocytokine using a matrix metalloprotease (MMP) sensitive linker (PSL). Conclusion-MDNA113 is a tumor-targeting and conditional-activatable anti-PD1/IL-2SK fusion characterized with potent PD1/PDL1 blockade and 'not-alpha, beta enhanced' IL-2R agonism. MDNA113 is better tolerated than the non-mask version while achieving similar effect on tumor control, therefore offering a much broader therapeutic index."

Clinical • IO biomarker • Oncology • Solid Tumor • CD8 • IL13 • STAT5 • STAT5AWqe

Characterization of a tumor-targeting and activatable T-MASK platform to enhance tumor accumulation and tolerability of potent immune modulators (SITC 2023) - "MDNA213 is fused via a PSL to MDNA11 and MDNA223, both containing a not-alpha, beta-enhanced IL-2 fused with albumin or anti-PD1 antibody respectively. Conclusions MDNA113 is a novel T-MASK construct designed to increase tolerability while leveraging the synergy between PD1/PDL-1 blockade and IL-2R agonism for immunotherapy. Ongoing studies investigate alternative tumor-targeting/masking domains and immune modulators, including other cytokines and potent therapeutic agents, to potentially broaden the utility of the T-MASK platform."

Oncology • Solid Tumor • IL13 • IL2RA • STAT5 • STAT5AWqe

Medicenna Presents Preclinical IL-13 Superkine Data at the AACR Annual Meeting (GlobeNewswire) - "The data presented at AACR demonstrates the ability of our IL-13 Superkines to preferentially accumulate in the microenvironment of IL-13Rα2-expressing tumors, enabling development of first-in-class precision immunotherapies that can selectively deliver a variety of therapeutic payloads....The AACR poster includes data demonstrating that both MDNA132 and MDNA213 exhibit highly selective binding to the IL-13 decoy receptor (IL-13Rα2) and, in a murine model, selectively accumulate in the tumor microenvironment (TME) for several days."

Preclinical • Oncology • Solid Tumor